Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06910306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 3 sitesv7
  2. Site details revised at 2 of 3 sitesv6
  3. Study sites: 1 to 3v5
  4. Study title shortened, about 8 wordsv4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 1, 2025 to Oct 1, 2025
    • Site details revised
    v3
  6. Start date: May 1, 2025 to Sep 1, 2025v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Alpha Tau Medical LTD.
20 trials monitored
See all monitored trials
Glioma
1,251 trials monitored
See 88 trials at risk
Glioblastoma
710 trials monitored
See 52 trials at risk
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
Trial Details
NCT Number NCT06910306
Lead Sponsor Alpha Tau Medical LTD.
Conditions
(from sponsor)		 Recurrent Glioblastoma, Recurrent Gliomas
Related terms Glioblastoma, Glioma
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov